Incidence and Clinical Practice of Exudative Age-related Macular Degeneration: A Nationwide Population-Based Cohort Study.
Incidence and Clinical Practice of Exudative Age-related Macular Degeneration: A Nationwide Population-Based Cohort Study.
复制标题
DOI：
10.1016/j.xops.2022.100125
复制
发表时间：
2022-06
影响因子：
--
通讯作者：
Tsujikawa, Akitaka
中科院分区：
文献类型：
--
作者：
Kido, Ai;Miyake, Masahiro;Tamura, Hiroshi;Hiragi, Shusuke;Kimura, Takeshi;Yoshida, Satomi;Takeuchi, Masato;Ohtera, Shosuke;Takahashi, Ayako;Ooto, Sotaro;Kawakami, Koji;Kuroda, Tomohiro;Tsujikawa, Akitaka
目的探讨活动性渗出型老年性黄斑变性（AMD）的发病率和治疗模式。使用日本国家健康保险索赔和特定健康检查数据库（NDB）进行的一项基于人群的队列研究，NDB是日本厚生劳动省（MHLW）管理的国家索赔数据库。日本40岁以上的总人口（7600万人）。在MHLW的许可下，我们访问了完整的NDB数据集，并确定了2011年至2018年期间新诊断的活动性渗出性AMD患者。在2011年至2018年期间，每年按年龄和性别对活动性渗出性AMD的发生率进行分类;此外，还获得了自初始治疗以来一线治疗和每年抗血管内皮生长因子（VEGF）注射次数的详细信息，并研究了治疗模式的变化。活动性渗出性AMD的发病率。在指定的8年期间，确定了246064例活动性渗出性AMD的事件病例;这些患者中有61.4%为男性。40岁或以上一般人群的总发病率为40.66/100 000人-年（95%置信区间[CI]，40.49-40.82），男性为53.22（95% CI，52.95-53.49），女性为29.78（95% CI，29.60-29.98）。男性的平均发病年龄低于女性（72.51 ± 10.50岁vs. 73.90 ± 10.46岁）。在新诊断的活动性渗出性AMD患者中，92.9%接受抗VEGF注射进行初始治疗，而1.8%接受光动力疗法的联合治疗。首次注射后第1年（0-12个月）、第2年（13-24个月）和第3年（25-36个月）的抗VEGF注射次数分别为3.66 ± 2.30、1.39 ± 2.20和1.23 ± 2.19。在第一年接受较少注射的患者在随后几年接受较少注射，反之亦然。这是一项关于临床实践中活动性渗出性AMD的详细流行病学和实际治疗模式的相对大规模人群研究。我们的研究结果可以成为确保眼睛健康和促进所有年龄段所有人福祉的基本信息来源。
To elucidate the incidence and treatment pattern of active exudative age-related macular degeneration (AMD). A population-based cohort study conducted using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), a national claims database managed by the Japanese Ministry of Health, Labour, and Welfare (MHLW). The entire Japanese population aged 40 years or older (76 million people). With the permission of the MHLW, we accessed the complete NDB dataset and identified patients with newly diagnosed active exudative AMD between 2011 and 2018. The incidence of active exudative AMD was categorized by age and sex per year between 2011 and 2018; moreover, details regarding first-line therapy and number of anti-vascular endothelial growth factor (VEGF) injections per elapsed year since initial treatment were obtained and changes in treatment pattern were investigated. Incidence rate of active exudative AMD. During the specified 8-year period, 246 064 incident cases of active exudative AMD were identified; 61.4% of these patients were men. The overall incidence rate was 40.66 per 100 000 person-years (95% confidence interval [CI], 40.49–40.82) in the general population aged 40 years or older, 53.22 (95% CI, 52.95–53.49) in men, and 29.78 (95% CI, 29.60–29.98) in women. Mean age of onset was lower in men than in women (72.51 ± 10.50 years vs. 73.90 ± 10.46 years). Among patients with newly diagnosed active exudative AMD, 92.9% received anti-VEGF injections for initial treatments, whereas 1.8% underwent combination therapy with photodynamic therapy. The number of anti-VEGF injections in the first year (0–12 months), second year (13–24 months), and third year (25–36 months) after the initial injection was 3.66 ± 2.30, 1.39 ± 2.20, and 1.23 ± 2.19, respectively. Patients who received fewer injections in the first year received fewer injections in subsequent years and vice versa. This is a relatively large population-based study on the detailed epidemiology and actual treatment patterns of active exudative AMD in clinical practice. Our results can be a fundamental information source to ensure healthy eyes and promote well-being for all at all ages.
登录
查看更多内容
影响因子：
4.1
作者：
Kido, Ai;Miyake, Masahiro;Tamura, Hiroshi;Hiragi, Shusuke;Kimura, Takeshi;Ohtera, Shosuke;Takahashi, Ayako;Ooto, Sotaro;Kawakami, Koji;Kuroda, Tomohiro;Tsujikawa, Akitaka
通讯作者：
Tsujikawa, Akitaka
影响因子：
4.6
作者：
Sasaki M;Harada S;Kawasaki Y;Watanabe M;Ito H;Tanaka H;Takeuchi A;Tsubota K;Takebayashi T;Nishiwaki Y;Kawasaki R
通讯作者：
Kawasaki R
影响因子：
2.9
作者：
Kido A;Tamura H;Ikeda HO;Miyake M;Hiragi S;Tsujikawa A
通讯作者：
Tsujikawa A
影响因子：
13.7
作者：
Cheung, Chui Ming Gemmy;Ong, Peng Guan;Wong, Tien Yin
通讯作者：
Wong, Tien Yin
影响因子：
4.1
作者：
Miyazaki, M;Nakamura, H;Nose, Y
通讯作者：
Nose, Y